Every medicine in a pharmacy — from a common painkiller to a cutting-edge cancer drug — travelled the same long road before it was approved for sale. That road runs through clinical trials: carefully designed experiments in human volunteers that test whether a new treatment is safe and whether it actually works. In the United States, the Food and Drug Administration (FDA) typically requires three stages of human testing before a drug can be approved, with a fourth stage continuing after approval. Understanding how these stages work explains both why new medicines take years to arrive — and why that wait is deliberate.

Before the first volunteer: lab and animal testing

Human trials never begin with humans. Researchers first develop and test a potential treatment in laboratories, then in animal studies. Only the most promising candidates advance to testing in people, and every trial follows a written protocol that spells out who can take part, what procedures will be done, and how long the study will last. Regulatory agencies and ethics review boards must approve the protocol before a single volunteer is enrolled, and participants are told exactly what the trial involves before they agree to join.

Phase I: is it safe, and at what dose?

Phase I is the first time an experimental treatment is given to people. The group is small — typically 20 to 80 volunteers, according to the U.S. National Institute on Aging — and the goal is not to cure anyone. Researchers are answering two narrower questions: is the treatment safe, and what dose can people tolerate? Volunteers are watched closely for side effects, different dosage levels are tested, and researchers learn how the drug is absorbed and processed by the body. Because so little is known about the risks at this stage, these trials are usually short, lasting several months, and they are often conducted in healthy volunteers — though for serious illnesses such as cancer, participants are usually patients with the disease. Many experimental drugs never make it past this stage.

Phase II: is there a signal that it works?

If a treatment looks reasonably safe, it moves to Phase II, which involves a larger group — roughly 100 to 300 people who actually have the condition the drug is meant to treat. The purpose shifts: researchers now look for preliminary evidence that the drug is effective, while continuing to monitor safety and short-term side effects. These trials often run from several months to about two years. Phase II is a filtering step. A drug that shows no meaningful benefit here is unlikely to justify the enormous cost of the next stage, so many candidates are abandoned at this point.

Phase III: the decisive head-to-head comparison

Phase III is the pivotal stage — the large, rigorous trial whose results usually determine whether a drug gets approved. Several hundred to a few thousand volunteers take part (the FDA’s typical range is 300 to 3,000, often over one to four years), drawn from different populations and tested at different dosages. Crucially, the new treatment is compared directly against either the current standard treatment or a placebo. Most Phase III drug trials are designed as randomized, double-blind, and placebo-controlled studies — the gold-standard design described below. If the FDA concludes that the results support the drug’s use for a particular condition, it approves the treatment for clinical use.

Phase IV: watching the drug after approval

Approval is not the end of the story. Phase IV trials take place after a drug is on the market, monitoring its safety and effectiveness in large, diverse populations over long periods. Some side effects are too rare — or take too long to appear — to show up in a Phase III trial of a few thousand people, and only emerge once hundreds of thousands of patients use the drug. Phase IV studies can also explore new uses for an approved medicine, different ways of administering it, or how it performs in specific groups such as older adults or people taking other medications. Findings from this stage can still change a drug’s labelling or how doctors are advised to use it.

The machinery of trust: randomization, blinding and placebos

The design of a modern trial is as important as its size, because human biology — and human psychology — can easily mislead. Four features guard against that:

• Randomization. Participants are assigned by chance — usually by computer — to the treatment group or the control group. Random assignment balances both known and unknown factors (age, genetics, lifestyle) across the groups, so any difference in outcomes can more confidently be attributed to the treatment itself.
• A control group. The control group receives either a placebo or the current standard of care, giving researchers a baseline for comparison. For serious diseases such as cancer, the control group normally receives the standard treatment rather than nothing — placebos are generally used only when no proven treatment exists.
• Placebos. A placebo is an inactive pill, liquid or procedure that looks identical to the real treatment. It lets researchers separate the treatment’s genuine effect from the placebo effect — the well-documented phenomenon of people feeling better simply because they believe they are being treated.
• Blinding. In a single-blind trial, participants do not know which group they are in; in a double-blind trial, neither the participants nor the researchers know. Blinding prevents expectations — from patients and doctors alike — from distorting the results.

Together, these features make the randomized controlled trial the most reliable tool medicine has for establishing cause and effect. They are also why a promising result in a small, early-phase trial should never be treated as proof: each phase answers a different question, and only the full sequence — safety, then efficacy signals, then large-scale confirmation — earns a treatment its place in the clinic.

FAQs

Do clinical trial volunteers get paid?

Often, yes — many trials offer modest compensation for participants’ time and travel, though amounts vary widely. Participation is always voluntary, and volunteers are free to leave a trial at any time. Trials also typically cover the medical costs related to the study itself.

Is it ethical to give some patients a placebo?

Ethics boards review every trial design before it begins. When an effective treatment already exists, the control group usually receives that standard treatment rather than a placebo, so nobody is denied known care. Placebo-only control groups are generally reserved for situations where no proven treatment exists.

How long does the whole clinical trial process take?

Years. Individual phases run from several months (Phase I) to one to four years (Phase III), and the full journey from first human dose to approval commonly stretches over most of a decade once the earlier laboratory work is included.

Can a trial be stopped before it finishes?

Yes. Independent monitoring committees watch trial data as it accumulates, and a trial can be halted early if the treatment proves clearly harmful, clearly ineffective — or, occasionally, so convincingly effective that it would be unethical to keep the control group waiting.

Compiled by the Khabar 24h Editorial Desk from publicly available sources.